^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | iadademstat (ORY-1001) (LSD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
712 Iadademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial
Published date:
11/03/2022
Excerpt:
...we present the results of the Phase 2 ALICE study (EudraCT 2018-000482-36) testing the combination of iada plus aza for the frontline treatment of unfit AML patients...Response assessment per specific mutations shows that 3 out of 3 (3/3) with FLT3 mutations, 7/7 with RAS pathway mutations, and 6/8 pts with TP53 mutations responded.
Secondary therapy:
azacitidine
DOI:
https://doi.org/10.1182/blood-2022-168945
Trial ID:
